Fredun Pharmaceuticals Limited has fixed June 23, 2026, as the record date for the payment of a final dividend for the financial year 2025-26. The company announced a dividend of 7% on equity shares with a face value of ₹10 each. This entitlement is subject to the approval of shareholders at the ensuing Annual General Meeting.

The record date of Tuesday, June 23, 2026, has been established to ascertain the members eligible for the payout. The dividend recommendation comes from the Board of Directors. If approved, the payment will be made within 30 days from the date of the Annual General Meeting, subject to the deduction of tax at source.

The intimation was submitted to BSE Limited pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was confirmed by Fredun Nariman Medhora, Managing Director of the company.

Dividend Details

Fredun Pharmaceuticals Limited announced its audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2026, on May 25, 2026. The company reported strong financial performance with substantial growth in revenue, profitability, and operating margins across both the full year and the fourth quarter. The Board of Directors recommended a final dividend of ₹0.70 per equity share and approved a 2:1 bonus issue, signaling confidence in future growth.

Financial Performance

For the fiscal year 2025-26, the company reported a standalone net profit of ₹33.21 crore, compared to ₹20.81 crore in the previous year. Total income from operations rose to ₹639.12 crore from ₹456.27 crore in the prior year. The fourth quarter also reflected robust year-on-year growth, with net profit climbing to ₹11.07 crore from ₹7.07 crore in the same period of the previous year. Quarterly revenue grew to ₹213.05 crore compared to ₹167.41 crore in the corresponding prior-year period.

Key Financial Metrics

The following table summarizes the standalone financial performance for the year ended March 31, 2026, alongside the quarterly comparison:

Operating Performance

The company's quarterly operating performance showed a marked improvement, with Q4 EBITDA rising to ₹29.13 crore from ₹17.44 crore in the same period of the previous year. The EBITDA margin expanded significantly to 13.67% from 10.42% year-on-year, reflecting improved operational efficiency and better cost management during the quarter.

Board Decisions

The Board of Directors recommended a final dividend of ₹0.70 per equity share for the financial year 2025-26. This dividend is subject to shareholder approval at the ensuing Annual General Meeting. Additionally, the board approved the issuance of bonus shares to shareholders and warrant holders in the ratio of 2:1, meaning shareholders will receive two fully paid-up bonus equity shares of ₹10 each for every one existing equity share held. The record date for determining eligibility will be intimated in due course.

Corporate Actions

In other corporate decisions, the board approved an increase in the authorized share capital from ₹10 crore to ₹50 crore, subject to shareholder approval. The company also appointed M/s. Nikhil Maniar & Associates as Internal Auditor and M/s. Joshi Apte & Associates as Cost Auditor for the financial year 2026-2027. The statutory auditors issued an unmodified opinion on the standalone and consolidated financial results.